Reuters -- Swiss Santhera is aiming to seek approval for lead drug Catena to treat a rare eye disease in the first half of 2011 after a trial showed it improved sight, boosting the biotech group’s prospects.
Reuters -- Swiss Santhera is aiming to seek approval for lead drug Catena to treat a rare eye disease in the first half of 2011 after a trial showed it improved sight, boosting the biotech group’s prospects.
